Search results for "bispecific"
Article
Buffer optimization for separation of bsAb in a capture step using MabSelect™ VL resin
Protein L resins bind to kappa light chain and are often used to purify antibody fragments such as dAbs and Fabs — but they can also be used to remove product-related impurities from bispecif…
Article
Get Started: Purification of mAb Variants - eLearning
The success of monoclonal antibodies (mAbs) as therapeutics and the multi-domain structure of antibodies has made it possible to create antibody variants, such as bispecific antibodies (bsAbs)…
Article
Chromatography innovations for the diversified antibody pipeline
MabSelect™ VH3 resins provides efficiency in capture of bispecific antibodies and antibody fragments such as Fab, scFv, and VHH. Discover how we’re supporting the diverse antibody pipelines with chrom…
Article
eBook: Purification of Antibody Therapeutics - Approach for Diversified Pipeline
Today, we see multispecific and bispecific antibodies, antibody fragments, and antibody drug conjugates in the development pipeline. Manufacturing platform approaches conveniently used for many tradit…
Article
Platform for Purification of VHH-type Antibody Fragments
Click here to read this poster >>
Protein A affinity chromatography resins have been used to purify monoclonal antibodies (mAbs) by the bioprocess industry at all scales for a long time. Howev…
Article
The Challenge of Disruptive Technologies in Bioprocessing
The industry pipeline is growing in complexity to include emerging molecules such as bispecific antibodies, antibodydrug conjugates (ADCs), and those viral vectors for gene and cell therapies. Some of…
Article
Process Chromatography: Continuous Optimization
Most chromatography vendors have developed new affinity resins designed for use with the next-generation biologic products being developed today, including antibody fragments, bispecific antibodies, a…
Article
A Risk-Based Genetic Characterization Strategy for Recombinant CHO Cell Lines Used for Clinical and Commercial Applications
This early screening approach has identified cryptic aberrant splice sites in multiple therapeutic candidates including monoclonal antibodies, bispecific antibodies, and fusion proteins, therefore pre…
Article
A Bright Future for the Plasma Fractionation Industry
Nash concluded by stating that potentially an even bigger impact on the treatment of hemophilia patients could come from bispecific antibodies. These molecules might prevent development of inhibitors …
Article
Downstream Process Developers: What are Your Antibody Processing Challenges?
Process developers, we want to hear from you! We're asking PD scientists to tell us about their biggest challenges developing downstream processes for mAbs and their variants.
Take this …